Skip to main content
MedPathMedPath Home
Clinical Trials/NCT06603506
NCT06603506
Recruiting
Not Applicable

Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

Centre Francois Baclesse1 site in 1 country16 target enrollmentNovember 21, 2024
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsEndometrial Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Endometrial Cancer
Sponsor
Centre Francois Baclesse
Enrollment
16
Locations
1
Primary Endpoint
Rate of establishment of exploitable tumor organoid lines
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

This study comprises 3 stages:

  1. Collection of tumor and blood samples.
  2. Creation of organoid models based on tumor samples.
  3. Development of functional tests to predict clinical response to treatment.
Registry
clinicaltrials.gov
Start Date
November 21, 2024
End Date
October 15, 2027
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
Centre Francois Baclesse
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Patient aged 18 years or more
  • •Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
  • •Patient with localized endometrial cancer, presenting:
  • •A high-grade endometrioid histological type and/or
  • •P53 mutation and/or
  • •a non-endometrioid histological type regardless of P53 status.
  • •Patient affiliated to a social security scheme
  • •Information and signature of informed consent prior to any specific study procedure

Exclusion Criteria

  • •Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
  • •Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.

Outcomes

Primary Outcomes

Rate of establishment of exploitable tumor organoid lines

Time Frame: through study completion, an average of 3 years

Rate of establishment of tumor organoid lines usable for predictive assays of response to PARP inhibitors.

Study Sites (1)

Loading locations...

Similar Trials

Not yet recruiting
Not Applicable
Construction of Gynecological Tumor OrganoidsGynecologic CancerOrganoid
NCT06155370Peking Union Medical College Hospital200
Recruiting
Not Applicable
Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic DecisionsUndifferentiated Carcinoma
NCT06612827Centre Francois Baclesse20
Unknown
Not Applicable
Tissue Bank of Biological Specimens From Patients With Gynecologic DiseaseEndometrial NeoplasmsUterine Cervical NeoplasmsOvarian NeoplasmsLeiomyoma
NCT00299481U.S. Army Medical Research and Development Command7,000
Recruiting
Not Applicable
Individualized Precision Treatment Based on Ovarian Cancer Organoid ModelOvarian Cancer
NCT05813509The First Affiliated Hospital of Xiamen University30
Completed
Not Applicable
Collecting Tumor Samples From Patients With Gynecological TumorsBorderline Ovarian Clear Cell TumorBorderline Ovarian Serous TumorCervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Small Cell CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedChildhood Embryonal RhabdomyosarcomaChildhood Malignant Ovarian Germ Cell TumorEndometrioid Stromal SarcomaGestational Trophoblastic TumorMalignant MesotheliomaMalignant Ovarian Epithelial TumorMelanomaNeoplasm of Uncertain Malignant PotentialOvarian Brenner TumorOvarian Clear Cell CystadenocarcinomaOvarian Serous CystadenocarcinomaPaget Disease of the VulvaRecurrent Cervical CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Germ Cell TumorRecurrent Primary Peritoneal CarcinomaRecurrent Uterine Corpus CarcinomaRecurrent Vaginal CarcinomaRecurrent Vulvar CarcinomaStage I Ovarian CancerStage I Uterine Corpus CancerStage I Vaginal CancerStage I Vulvar CancerStage IA Cervical CancerStage IA Fallopian Tube CancerStage IA Ovarian CancerStage IA Ovarian Germ Cell TumorStage IB Cervical CancerStage IB Fallopian Tube CancerStage IB Ovarian CancerStage IB Ovarian Germ Cell TumorStage IC Fallopian Tube CancerStage IC Ovarian CancerStage IC Ovarian Germ Cell TumorStage II Ovarian CancerStage II Uterine Corpus CancerStage II Vaginal CancerStage II Vulvar CancerStage IIA Cervical CancerStage IIA Fallopian Tube CancerStage IIA Ovarian CancerStage IIA Ovarian Germ Cell TumorStage IIB Cervical CancerStage IIB Fallopian Tube CancerStage IIB Ovarian CancerStage IIB Ovarian Germ Cell TumorStage IIC Fallopian Tube CancerStage IIC Ovarian CancerStage IIC Ovarian Germ Cell TumorStage III Borderline Ovarian Surface Epithelial-Stromal TumorStage III Cervical CancerStage III Uterine Corpus CancerStage III Vaginal CancerStage III Vulvar CancerStage IIIA Fallopian Tube CancerStage IIIA Ovarian CancerStage IIIA Ovarian Germ Cell TumorStage IIIA Primary Peritoneal CancerStage IIIB Fallopian Tube CancerStage IIIB Ovarian CancerStage IIIB Ovarian Germ Cell TumorStage IIIB Primary Peritoneal CancerStage IIIC Fallopian Tube CancerStage IIIC Ovarian CancerStage IIIC Ovarian Germ Cell TumorStage IIIC Primary Peritoneal CancerStage IV Borderline Ovarian Surface Epithelial-Stromal TumorStage IV Fallopian Tube CancerStage IV Ovarian CancerStage IV Primary Peritoneal CancerStage IV Uterine Corpus CancerStage IVA Cervical CancerStage IVA Vaginal CancerStage IVB Cervical CancerStage IVB Vaginal CancerStage IVB Vulvar CancerUterine Corpus CancerUterine Corpus LeiomyosarcomaVulvar Squamous Cell Carcinoma
NCT00897442Gynecologic Oncology Group275